|
Depressive disorder
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
The association of endocannabinoid receptor genes (CNR1 and CNR2) polymorphisms with depression: A meta-analysis.
|
31725603 |
2019 |
|
Depressive disorder
|
0.550 |
Biomarker
|
disease |
PSYGENET |
Pharmacological manipulation of CB2 receptors is a potential therapeutic strategy for the treatment of stress-related pathologies with a neuroinflammatory component, such as depression.
|
24467609 |
2014 |
|
Depressive disorder
|
0.550 |
Biomarker
|
disease |
PSYGENET |
Given the evidence for the role of the endocannabinoid system in the pathogenesis of depression as well as in the mediation of antidepressant drug effects, the aim of this study was to analyze genetic variability in the endocannabinoid system genes (CNR1, CNR2 and FAAH genes) and their role in clinical response (at week 4) and remission (at week 12) in SSRI (citalopram) treatment in a sample of 154 depressive outpatients, all of Spanish origin.
|
22826533 |
2012 |
|
Depressive disorder
|
0.550 |
Biomarker
|
disease |
BEFREE |
Given the evidence for the role of the endocannabinoid system in the pathogenesis of depression as well as in the mediation of antidepressant drug effects, the aim of this study was to analyze genetic variability in the endocannabinoid system genes (CNR1, CNR2 and FAAH genes) and their role in clinical response (at week 4) and remission (at week 12) in SSRI (citalopram) treatment in a sample of 154 depressive outpatients, all of Spanish origin.
|
22826533 |
2012 |
|
Depressive disorder
|
0.550 |
Biomarker
|
disease |
PSYGENET |
Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors.
|
20649579 |
2010 |
|
Depressive disorder
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
In this study we tested the hypothesis that genetic variants of the CB2 gene might be associated with depression in a human population and that alteration in CB2 gene expression may be involved in the effects of abused substances, including opiates, cocaine, and ethanol, in rodents.
|
18991891 |
2008 |
|
Depressive disorder
|
0.550 |
Biomarker
|
disease |
CTD_human |
In this study we tested the hypothesis that genetic variants of CB2 gene might be associated with depression in a human population and that alteration in CB2 gene expression may be involved in the effects of abused substances including opiates, cocaine and ethanol in rodents.
|
18286196 |
2008 |
|
Depressive disorder
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
In this study we tested the hypothesis that genetic variants of CB2 gene might be associated with depression in a human population and that alteration in CB2 gene expression may be involved in the effects of abused substances including opiates, cocaine and ethanol in rodents.
|
18286196 |
2008 |
|
Depressive disorder
|
0.550 |
Biomarker
|
disease |
PSYGENET |
In this study we tested the hypothesis that genetic variants of the CB2 gene might be associated with depression in a human population and that alteration in CB2 gene expression may be involved in the effects of abused substances, including opiates, cocaine, and ethanol, in rodents.
|
18991891 |
2008 |
|
Depressive disorder
|
0.550 |
Biomarker
|
disease |
PSYGENET |
In this study we tested the hypothesis that genetic variants of CB2 gene might be associated with depression in a human population and that alteration in CB2 gene expression may be involved in the effects of abused substances including opiates, cocaine and ethanol in rodents.
|
18286196 |
2008 |
|
Depressive disorder
|
0.550 |
Biomarker
|
disease |
BEFREE |
We have reported the discovery and functional presence of CB2 cannabinoid receptors in mammalian brain that may be involved in depression and drug abuse and this was supported by reports of identification of neuronal CB2 receptors that are involved in emesis.
|
17105950 |
2006 |
|
Pancreatitis
|
0.510 |
Biomarker
|
disease |
RGD |
Finally, in rat pancreatic acinar cells, CB1- and CB2-receptors, expressed both in basal conditions and after CK-induced pancreatitis but inactive on amylase secretion, have an unknown role both in physiological and pathological conditions.
|
19070664 |
2009 |
|
Pancreatitis
|
0.510 |
Biomarker
|
disease |
CTD_human |
Antagonists at CB1- and CB2-receptors were effective in reversing HU210-induced antinociception, whereas a combination of CB1- and CB2-antagonists was required to block the anti-inflammatory effects of HU210 in pancreatitis.
|
17484889 |
2007 |
|
Pancreatitis
|
0.510 |
Biomarker
|
disease |
BEFREE |
Antagonists at CB1- and CB2-receptors were effective in reversing HU210-induced antinociception, whereas a combination of CB1- and CB2-antagonists was required to block the anti-inflammatory effects of HU210 in pancreatitis.
|
17484889 |
2007 |
|
Atherosclerosis
|
0.360 |
Biomarker
|
disease |
BEFREE |
We described the role of classical components of the eCB system (eCBs, CB1 and CB2 receptors) and eCB-related lipids, their regulatory enzymes and molecular targets in atherosclerosis.
|
31448709 |
2019 |
|
Atherosclerosis
|
0.360 |
Biomarker
|
disease |
BEFREE |
The discovery that Δ-9-tetrahydrocannabinol (Δ9-THC), the main active constituent of marijuana, inhibited atherosclerotic plaque progression via a cannabinoid 2 (CB(2) ) receptor-dependent anti-inflammatory mechanism, and that certain natural and synthetic cannabinoid ligands could modulate the myocardial or cerebral ischaemia-reperfusion-induced tissue damage, have stimulated impetus for a growing number of studies investigating the implication of CB(2) receptors in atherosclerosis, restenosis, stroke, myocardial infarction and heart failure.
|
22612332 |
2012 |
|
Atherosclerosis
|
0.360 |
Biomarker
|
disease |
BEFREE |
Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules.
|
20075743 |
2010 |
|
Atherosclerosis
|
0.360 |
Biomarker
|
disease |
BEFREE |
These results suggest that CB2 expression increases the susceptibility of macrophages to OxLDL-induced apoptosis, in part, by modulating the effect of oxysterols on the Akt survival pathway and that CB2 may influence atherosclerosis by modulating lesional macrophage apoptosis.
|
18614816 |
2008 |
|
Atherosclerosis
|
0.360 |
Biomarker
|
disease |
BEFREE |
Because the above-mentioned TNF-alpha-induced phenotypic changes are critical in the initiation and progression of atherosclerosis and restenosis, our findings suggest that targeting CB(2) receptors on endothelial cells may offer a novel approach in the treatment of these pathologies.
|
17660390 |
2007 |
|
Atherosclerosis
|
0.360 |
Therapeutic
|
disease |
CTD_human |
Thus, THC or cannabinoids with activity at the CB2 receptor may be valuable targets for treating atherosclerosis.
|
15815632 |
2005 |
|
Atherosclerosis
|
0.360 |
Biomarker
|
disease |
BEFREE |
Thus, THC or cannabinoids with activity at the CB2 receptor may be valuable targets for treating atherosclerosis.
|
15815632 |
2005 |
|
Mental Depression
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
The association of endocannabinoid receptor genes (CNR1 and CNR2) polymorphisms with depression: A meta-analysis.
|
31725603 |
2019 |
|
Mental Depression
|
0.350 |
Biomarker
|
disease |
PSYGENET |
Pharmacological manipulation of CB2 receptors is a potential therapeutic strategy for the treatment of stress-related pathologies with a neuroinflammatory component, such as depression.
|
24467609 |
2014 |
|
Mental Depression
|
0.350 |
Biomarker
|
disease |
PSYGENET |
Given the evidence for the role of the endocannabinoid system in the pathogenesis of depression as well as in the mediation of antidepressant drug effects, the aim of this study was to analyze genetic variability in the endocannabinoid system genes (CNR1, CNR2 and FAAH genes) and their role in clinical response (at week 4) and remission (at week 12) in SSRI (citalopram) treatment in a sample of 154 depressive outpatients, all of Spanish origin.
|
22826533 |
2012 |
|
Mental Depression
|
0.350 |
Biomarker
|
disease |
BEFREE |
Given the evidence for the role of the endocannabinoid system in the pathogenesis of depression as well as in the mediation of antidepressant drug effects, the aim of this study was to analyze genetic variability in the endocannabinoid system genes (CNR1, CNR2 and FAAH genes) and their role in clinical response (at week 4) and remission (at week 12) in SSRI (citalopram) treatment in a sample of 154 depressive outpatients, all of Spanish origin.
|
22826533 |
2012 |